Publication
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Related publications (33)
Immunosuppressive roles of Activin-A in melanoma and characterization of its precursor cleavage
Activin-A, a transforming growth factor êµ family member, is a pleiotropic cytokine with diverse functions in development, fertility, adult tissue homeostasis, and aging. Accordingly, deregulation of Activin-A signaling has been associated with many patho ...
EPFL2022An autonomous microfluidic device for identification and analysis of individual clinically-relevant mammalian cells
Fabien Louis Claude Robert Jammes
Cancer represents one of the major public health challenges worldwide, representing more than 25% of all deaths in the European Union in 2014. It affects a large and growing part of the general population, with the National Cancer Institute (NCI) estimatin ...
EPFL2021Bioengineering Methods to Improve in vitro Adoptive Cell Therapy based on Tumor-Infiltrating Lymphocytes
Cancer is one of the biggest medical challenges of our times, with a devastating impact across all social categories. Accordingly, considerable efforts are geared towards improving the standard of care. Among them, immunotherapy, which relies on the immune ...
EPFL2020Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Jeffrey Alan Hubbell, Melody Swartz, Seung Tae Lee, Lambert Charles François Potin, Jun Ishihara, Kazuto Fukunaga, Michal Mateusz Raczy
Cancer immunotherapy with immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune system activation. Here, we addressed ...
AMER ASSOC ADVANCEMENT SCIENCE2019Anti-angiogenic immunotherapy for lung cancer
Lung cancer is the leading cause of cancer-associated deaths worldwide. Platinum-based chemotherapy is the most common therapeutic approach in advanced non-small cell lung cancer (NSCLC), particularly for tumors that carry non-druggable activating mutation ...
EPFL2019The antimicrobial peptide defensin cooperates with tumour necrosis factor to drive tumour cell death in Drosophila
Bruno Lemaitre, Anna Dostalova
Antimicrobial peptides (AMPs) are small cationic molecules best known as mediators of the innate defence against microbial infection. While in vitro and ex vivo evidence suggest AMPs' capacity to kill cancer cells, in vivo demonstration of an anti-tumour r ...
ELIFE SCIENCES PUBLICATIONS LTD2019Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic Drug for Melanoma Treatment
Paul Joseph Dyson, Tina Riedel, Olivier Pierre Zava
By screening a drug library comprising FDA approved compounds, we discovered a potent interaction between the antifungal agent haloprogin and the experimental organometallic drug RAPTA-T, to synergistically induce cancer cell killing. The combination of th ...
2018Development of a nano-adjuvant cancer vaccine and its evaluation for melanoma in combination with radiotherapy
Cancer is the second leading cause of death in the world and melanoma is the deadliest type of skin cancer. Although surgery, radiotherapy and chemotherapy are still standard treatments, the discovery of the role played by the immune system in cancer has a ...
EPFL2018New roles of the lymphatic endothelium in modulating adaptive immunity: implications for immune tolerance and cancer immunotherapy
Lambert Charles François Potin
Lymphatic vessels have traditionally been considered as passive conduits for interstitial fluid drainage and for immune cell trafficking to lymph nodes. In the last two decades, many studies have challenged this classical dogma: lymphatic endothelial cells ...
EPFL2018Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Jeffrey Alan Hubbell, Melody Swartz, Lambert Charles François Potin, Martina Damo, Jun Ishihara, Kazuto Fukunaga
CD40 is an immune costimulatory receptor expressed by antigen-presenting cells. Agonistic anti-CD40 antibodies have demonstrated considerable antitumor effects yet can also elicit serious treatment-related adverse events, such as liver toxicity, including ...
AMER ASSOC CANCER RESEARCH2018